Paper9854472
Caffeine-potentiated chemotherapy and conservative surgery for high-grade soft-tissue sarcoma.
Tsuchiya H and 4 others. Anticancer Res, 1998. Cited by 37 papers, by iCite.
Cite this record
ConductScience Library. Caffeine-potentiated chemotherapy and conservative surgery for high-grade soft-tissue sarcoma. Papers, record 9854472. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9854472
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Caffeine-potentiated chemotherapy and conservative surgery for high-grade soft-tissue sarcoma.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Caffeine | Major topic |
| Sarcoma | Major topic |
| Soft Tissue Neoplasms | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Combined Modality Therapy | |
| Drug Synergism | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Male | |
| Middle Aged | |
| Preoperative Care | |
| Prospective Studies | |
| Survival Rate | |
| Treatment Outcome |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42684460 | Historical contributions and future horizons of Japanese orthopaedic oncology: from surgical innovation to nationwide collaborations. | Int Orthop | 2026 | https://conductscience.org/library/papers/42684460 | PubMed |
| 39064880 | Coffee Bean and Its Chemical Constituent Caffeine and Chlorogenic Acid as Promising Chemoprevention Agents: Updated Biological Studies against Cancer Cells. | Molecules | 2024 | https://conductscience.org/library/papers/39064880 | PubMed |
| 37242514 | Synergistic Effects of Caffeine in Combination with Conventional Drugs: Perspectives of a Drug That Never Ages. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37242514 | PubMed |
| 36275056 | Case report: Robust response of metastatic clear cell sarcoma treated with cabozantinib and immunotherapy. | Front Pediatr | 2022 | https://conductscience.org/library/papers/36275056 | PubMed |
| 31205866 | Clear cell sarcoma in unusual sites mimicking metastatic melanoma. | World J Clin Oncol | 2019 | https://conductscience.org/library/papers/31205866 | PubMed |
| 25031505 | Clinicopathological features, diagnosis and treatment of clear cell sarcoma/melanoma of soft parts. | Hippokratia | 2013 | https://conductscience.org/library/papers/25031505 | PubMed |
| 22041928 | Caffeine-potentiated chemotherapy for clear cell sarcoma: a report of five cases. | Int J Clin Oncol | 2013 | https://conductscience.org/library/papers/22041928 | PubMed |
| 18506562 | Gene therapy to enhance allograft incorporation after host tissue irradiation. | Clin Orthop Relat Res | 2008 | https://conductscience.org/library/papers/18506562 | PubMed |
| 17594092 | Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed. | Cancer Chemother Pharmacol | 2008 | https://conductscience.org/library/papers/17594092 | PubMed |
| 17418866 | Dual-color imaging of angiogenesis and its inhibition in bone and soft tissue sarcoma. | J Surg Res | 2007 | https://conductscience.org/library/papers/17418866 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9854472
GET https://conductscience.org/api/papers/v1/9854472/authors